Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Drug Assess ; 10(1): 10-17, 2020 Dec 16.
Article in English | MEDLINE | ID: mdl-33403155

ABSTRACT

AIMS: The ability of a patient to receive anti-cancer treatment depends on a variety of factors, including performance status (PS), which is typically measured using the Eastern Cooperative Oncology Group (ECOG) scale. This study hypothesized that there would be a strong and positive correlation between ECOG PS values and healthcare resource utilization (HCRU) and a strong and negative correlation with the use of anti-cancer therapy. MATERIALS AND METHODS: Patients with colorectal, lung or gastric cancer were included in this retrospective analysis of administrative claims data linked to electronic medical records (EMR). All-cause HCRU (hospitalization/inpatient care, emergency room visits, systemic anti-cancer therapy, radiation therapy, outpatient physician visits, hospice, home health care and key supportive care treatments such as anti-emetics, hematopoietic treatments, transfusions, and durable medical equipment) was evaluated by baseline ECOG PS value and PS over time. Adjusted multivariable regression analysis was used to assess the relationship between baseline ECOG PS and HCRU. Regression analyses were conducted to explore the relationship between other baseline variables and HCRU. RESULTS: There were 1311 patients included in this study. There was low correlation between PS and any HCRU variable or receipt of anti-cancer therapy (correlation coefficients all <0.10). In regression analyses, the proportion of patients with poor PS (PS = 2+) who were hospitalized was not significantly different from those with good PS (PS = 0/1) (28.9% versus 19.3%, p = .07). LIMITATIONS: The low rate of reporting of PS and the small sample size of patient groups in this study. CONCLUSIONS: There is very little evidence of a relationship between ECOG PS and HCRU, ECOG PS, or anti-cancer therapy in this study, in part due to low rates of and lack of variability in reported PS. There is some evidence that baseline comorbidities were significantly associated with HCRU and should be accounted for in future research evaluating HCRU.

2.
J Comp Eff Res ; 7(9): 923-934, 2018 09.
Article in English | MEDLINE | ID: mdl-29925271

ABSTRACT

AIM: A comparison of conventional pairwise propensity score matching (PSM) and generalized PSM method was applied to the comparative effectiveness of multiple treatment options for lung cancer. MATERIALS & METHODS: Deidentified data were analyzed. Covariate balances between compared treatments were assessed before and after PSM. Cox proportional hazards regression compared overall survival after PSM. RESULTS & CONCLUSION: The generalized PSM analyses were able to retain 61.2% of patients, while the conventional PSM analyses were able to match from 24.1 to 77.1% of patients from each treatment comparison. The generalized PSM achieved statistical significance (p < 0.05) in 8/10 comparisons, whereas conventional pairwise PSM achieved 1/10. The noted differences arose from different matched patient samples and the size of the samples.


Subject(s)
Lung Neoplasms/mortality , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Comparative Effectiveness Research , Female , Humans , Lung Neoplasms/drug therapy , Male , Middle Aged , Propensity Score , Retrospective Studies , Survival Analysis , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...